Navigation Links
Aethlon Medical Releases Shareholder Letter
Date:11/16/2011

olve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company’s clinical programs or provide market clearance of the company’s products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier’s® ability to capture exosomes and the impact it may have on disease conditions, the ability to successfully complete the Medanta HCV study and achieve positive results, the company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.

<
'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aethlon Medical to Present at IN3 Medical Innovation Summit on October 27th
2. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
3. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
4. "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.
5. Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
6. Aethlon Medical Releases Shareholder Letter
7. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
8. Aethlon Medical to Present the Aethlon ADAPT™ System at C21 BioVentures™ Life Sciences Partnering Conference
9. Aethlon Medical Clarifies News Report
10. ABC News Reports on Aethlon Medical
11. Aethlon Medical Announces Multi-Target Exosome Assay Validation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  Decision Resources Group finds that the laparoscopic ... will increase to a value of over $4.3 ... expansion in the large direct energy device market. In ... adopted due to the advantages they offer and as ... from Decision Resources Group,s coverage of the U.S. laparoscopic ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana ... a biopharmaceutical company focused on the licensing, development ... today announced positive results from its pivotal field ... for treating pain in dogs with osteoarthritis.  In ... pain assessment scores that were statistically significant compared ...
(Date:12/17/2014)... Germany , December 17, 2014 ... level of expenditure on research and development In ... increased its revenue by two percent to EUR 4.287 billion ... (EBIT) grew by 14 percent to EUR 360 million. "Overall, ... said Dr. Michael Kaschke , President and CEO of ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... SAN DIEGO, May 18, 2012  Ocera Therapeutics Inc., ... and commercialization of proprietary agents to treat gastrointestinal ... received a CE Mark for Zysa™ (spherical carbon ... predominant IBS (IBS-d), a condition affecting 10-15% of ...
... May 18, 2012  Actavis Group, an international generic ... FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, ... GlaxoSmithKline,s Requip® XL.  Actavis believes this is the ... Distribution of the product has commenced.   ...
Cached Medicine Technology:Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d) 2Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d) 3Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets) 2
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 ... that allege a metal-on-metal version of the artificial ... forward in state and federal courts, Bernstein Liebhard ... New Jersey’ Bergen County Superior Court on December ... permitted to begin deposition of plaintiffs on November ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer ... dress fans. The company has recently updated its official ... the holiday season, Angeldress Blog has recommended ... , Angeldress.co.uk prides itself in offering a huge selection ... All the company’s outfits are very carefully selected based ...
(Date:12/20/2014)... Aliso Viejo, California (PRWEB) December 20, 2014 ... have announced the release of a new plugin for ... Pixel Film Studios. , “TranSlice Volume 5 allows users ... literally hand draw it.” Said Christina Austin, CEO of ... to add level of professionalism while maintaining an easy ...
(Date:12/19/2014)... Today, Balfleet.com , a leading dress company ... dress promotion. All the old and new customers can ... Balfleet.com is well-known for its high quality trendy women’s ... dresses and more. Its formal dresses are quality made ... can create an elegant look when paired with any ...
(Date:12/19/2014)... 2014 The Plantrician Project ... educational events, tools and resources for healthcare professionals ... , the world’s leading online cooking school, have ... being needs: Culinary Rx. As an online food ... Rx, scheduled for debut spring 2015, will be ...
Breaking Medicine News(10 mins):Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4
... disorder, arterial trouble , FRIDAY, Oct. 12 (HealthDay News) ... pressure (CPAP) to treat people with obstructive sleep apnea ... the arteries -- within months, a new study finds. ... a direct link between obstructive sleep apnea and atherosclerosis, ...
... Calif., Oct. 12 Yesterday,Governor Schwarzenegger signed into ... to service and extend benefits to children and ... permanency. One important bill in this,package of legislation ... the current system of group home care into ...
... 12 The Agency for,Healthcare Research and Quality, part ... today the award of $41.6 million over the next ... centers as part of its,Centers for Education and Research ... the CERTs program. "Expanding the Centers for Education ...
... Shown to Prevent Post-Meal Oxidative Stress, FRESNO, Calif., ... It is probably a good idea based on health ... Health Effects of,Fruits and Vegetables in Houston, Texas this ... foods should be,consumed with each meal to prevent periods ...
... with the confusion of ... to their children, CINCINNATI, Oct. 12 All too ... give our children, especially,when it comes to the readily available ... as a frightening, but,important reminder that no medicine comes without ...
... Prior to Stroke, CLEVELAND, Oct. 12 Carotid ... today, are a significant risk factor,for stroke but many ... ultrasound screening is a successful tool for revealing,blocked carotid ... before death or,disability occurs. Life Line Screening, the ...
Cached Medicine News:Health News:Sleep Apnea Treatment Helps Stave Off Heart Disease 2Health News:California Alliance Applauds Governor's Support of Group Home Reform for Foster Youth 2Health News:California Alliance Applauds Governor's Support of Group Home Reform for Foster Youth 3Health News:AHRQ Expands Therapeutics Education and Research Centers and Adds New Topics: Health IT, Economics, Formularies 2Health News:AHRQ Expands Therapeutics Education and Research Centers and Adds New Topics: Health IT, Economics, Formularies 3Health News:Grape Consumption Improves Antioxidant Capacity in Humans 2Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 2Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 3Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 4Health News:Asymptomatic Carotid Artery Blockage a Significant Stroke Risk 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a scientifically advanced nutritional formulation that ... full body health. MacularProtect Complete-S, based ... other advanced research, delivers a diverse ... mg of FloraGLO® lutein and other ...
... PreserVision® Soft Gel Lutein patented formula is ... Lomb PreserVision® AREDS formula, with the beta-carotene ... Lutein is a carotenoid found in dark ... is highly concentrated in the macula, the ...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re...
Medicine Products: